Quick Verdict
BPC-157 and TB-500 are the two most studied recovery peptides in preclinical research. They work through completely different mechanisms — which is exactly why researchers study them together. BPC-157 dominates gut, tendon, and localized tissue repair. TB-500 leads in systemic cell migration, wound closure, and cardiac tissue. Neither is a substitute for the other.
All products sold by FenaLife are intended strictly for laboratory and academic research purposes. Not for human consumption, injection, or ingestion. These statements have not been evaluated by the FDA.
Compound Profiles at a Glance
| Property | BPC-157 | TB-500 |
|---|---|---|
| Full Name | Body Protection Compound 157 | Thymosin Beta-4 Fragment |
| Structure | 15 amino acids | 43 amino acids |
| Origin | Synthetic fragment of gastric juice protein | Synthetic fragment of Thymosin Beta-4 |
| Primary Mechanism | VEGF upregulation, NO modulation, growth factor signalling | G-actin sequestration, cell migration, angiogenesis |
| Half-Life | Short (hours) — frequent dosing in rodent studies | Longer biological activity window |
| WADA Status | Prohibited (S0, 2022) | Prohibited (S2, 2011) |
| FDA Status | Not approved — research compound | Not approved — research compound |
Mechanisms: How They Differ
BPC-157 Mechanism
BPC-157 acts through the nitric oxide (NO) system and vascular endothelial growth factor (VEGF) upregulation. In rodent studies it promotes angiogenesis at injury sites, modulates the FAK-paxillin pathway involved in cell survival and tendon healing, and exerts gastroprotective effects through prostaglandin and NO-dependent pathways. Its ability to survive the GI environment makes it one of the rare peptides with demonstrated oral bioavailability in animal models.
TB-500 Mechanism
TB-500 works through G-actin sequestration — it binds to actin monomers, reducing the pool available for polymerisation. This regulates cytoskeletal dynamics and promotes cell migration. It also upregulates MMP-2 (matrix metalloproteinase-2), which remodels extracellular matrix during repair, and stimulates angiogenesis through a pathway distinct from VEGF. Its systemic distribution makes it effective for injuries throughout the body, not just at the administration site.
Research Applications: Where Each Compound Leads
| Application Area | BPC-157 | TB-500 | Winner |
|---|---|---|---|
| Tendon & Ligament Repair | Strong preclinical data (Achilles, rotator cuff models) | Moderate data | BPC-157 |
| Gut & GI Healing | Extensive — NSAID damage, IBD models, fistula repair | Minimal data | BPC-157 |
| Wound Closure | Moderate | Strong — both cutaneous and deep tissue | TB-500 |
| Cardiac Tissue | Some data | Strong — cardiomyocyte protection models | TB-500 |
| Muscle Repair | Moderate | Strong — myosin upregulation, fibre regeneration | TB-500 |
| Neuroprotection | Strong — TBI, spinal cord, peripheral nerve models | Limited | BPC-157 |
| Bone Healing | Some data (fracture models) | Limited | BPC-157 |
| Systemic Distribution | Localised effect profile | Body-wide distribution | TB-500 |
Why Researchers Combine Them
The rationale for the BPC-157 + TB-500 stack (sometimes called the Wolverine Stack) is mechanism complementarity. BPC-157 handles vascularisation, inflammatory modulation, and site-specific repair. TB-500 handles cell migration, matrix remodelling, and systemic coverage. In tissue repair, both processes occur simultaneously — combining them addresses more of the healing cascade than either compound alone.
No chemical incompatibility has been reported in preclinical literature. Pre-blended formulations exist and have been verified by third-party testing (Janoshik) for compound identity and purity.
Storage & Handling Comparison
| Parameter | BPC-157 | TB-500 |
|---|---|---|
| Form | Lyophilised powder | Lyophilised powder |
| Pre-reconstitution storage | −20°C | −20°C |
| Post-reconstitution storage | 2–8°C, use within 28 days | 2–8°C, use within 28 days |
| Reconstitution solvent | Bacteriostatic water | Bacteriostatic water |
| Light sensitivity | Protect from light | Protect from light |
Frequently Asked Questions
Is BPC-157 or TB-500 better for tendon injuries?
BPC-157 has stronger and more extensive preclinical data specifically for tendon and ligament repair, including multiple Achilles tendon and rotator cuff rodent models. TB-500 has data for general soft tissue and muscle, but BPC-157 leads for tendon-specific applications in the research literature.
Can BPC-157 and TB-500 be mixed in the same vial?
No negative interactions have been reported in the literature. Pre-blended formulations are commercially available and have been third-party tested. When combining separately reconstituted peptides, researchers should ensure each compound’s purity is verified independently before mixing.
Which has a longer half-life — BPC-157 or TB-500?
TB-500 has a longer biological activity window due to its larger molecular structure and different clearance pathway. BPC-157 has a shorter half-life, which in rodent studies typically requires more frequent administration to maintain research concentrations.
Are BPC-157 and TB-500 legal to buy?
Both are available as research compounds in the United States and are not DEA-scheduled substances. In April 2026 the FDA removed both from its Category 2 restricted list, opening a clearer pathway for compounding pharmacy access. As research peptides, they are sold for laboratory use only and are not approved for human consumption.
Which should a researcher choose if they can only use one?
The answer depends on the research model. For gut, tendon, neurological, or highly localised injury models: BPC-157. For systemic tissue repair, wound closure, cardiac, or muscle fibre regeneration models: TB-500. For comprehensive tissue repair research covering multiple injury types: the combined stack.
Source Both Compounds at FenaLife
FenaLife supplies BPC-157 10mg and TB-500 10mg individually, each with Janoshik third-party COA. Free shipping on orders over $100.
See also: BPC-157 and TB-500 Stack Research Protocol Reference | TB-500 Research Guide
All products sold by FenaLife are intended strictly for laboratory and academic research purposes. Not for human consumption, injection, or ingestion. These statements have not been evaluated by the FDA.